CHRISTOPHER SHARIETT: Open Payments
NPI 1245655919 · PARRISH, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$430 in 22 payments from 10 companies in 2025. Trend: 2023 $58 · 2024 $199 · 2025 $430
Food & beverage: $430
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 4 | $77 |
| Corcept Therapeutics | 3 | $72 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $67 |
| Gilead Sciences, Inc. | 2 | $48 |
| ABBVIE INC. | 2 | $43 |
| Novo Nordisk Inc | 2 | $40 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $33 |
| Lilly USA, LLC | 1 | $19 |
| Merck Sharp & Dohme LLC | 1 | $18 |
| Amgen Inc. | 1 | $14 |
Products named: REXULTI, Korlym, CAPLYTA, Kerendia, VRAYLAR, Wegovy, MAVYRET, Ozempic.
Industry payments across AL — which companies pay providers there.
